- Possesses potent anti-inflammatory properties
- May help provide relief in situations of chronic pain (e.g. neurogenic, digestive, inflammatory, pelvic, muscular, etc.)
- Clinically proven micronised form
$61.96 incl. GST
Brand:
Used for: Allergies, Arthritis, Autoimmune conditions, Depression, Fibromyalgia, Migraines, Nerve Pain, Pain and Inflamation, fever
Categories: Pain and Inflammation, RN Labs
- Possesses potent anti-inflammatory properties
- May help provide relief in situations of chronic pain (e.g. neurogenic, digestive, inflammatory, pelvic, muscular, etc.)
- Clinically proven micronised form
| Micronised PEA 120 capsules | |
| Each Capsule Contains: | |
| Palmidrol (Palmitoylethanolamide) | 300 mg |
| Excipients: Leucine, Hypromellose (Capsule), Microcrystalline Cellulose, Calcium Hydrogen Phosphate Dihydrate, Colloidal Anhydrous Silica.
Suitable for vegans. |
|
IMPROVED NEUROPATHIC PAIN PERCEPTION
Studies show that where there is pain, tissue inflammation & damage within the nervous system, muscular & skeletal, integumentary, digestive, immune & lymphatic, renal and urinary systems, the application of PEA can be beneficial.
This is due to PEA’s binding capacity to neuronal receptors to modulate neuropathic and chronic pain, as well as inhibiting inflammation.
A study conducted by Esposito & Cuzzocrea demonstrated that PEA was able to modulate tissue injury associated with spinal cord trauma with significantly reduced spinal cord inflammation, with significantly ameliorated recovery of motor function through repeated administration 30 minutes before and 1 and 6 hours after trauma occurred.
IMPROVEMENT OF OSTEOARTHRITIC PAIN
Osteoarthritis (OA) is one of the most common degenerative diseases of joints. The Temporomandibular Joint (TMJ) is one of these joints. There are currently no disease modifying agents available in treating OA. Pain management is one of the key areas of focus in management of this condition, however, a major concern in the management of these patients is the risk of serious side effects of chronic Non-Steroidal Anti-Inflammatory drugs (NSAIDs) use.
A triple-blind randomised controlled trial compared the anti-inflammatory pain effects of Ibuprofen and PEA. Patients received 300mg of PEA in the morning and 600mg in the evening for 7 days, followed by a further 7 days of 300mg given twice daily. This was compared to 600mg of Ibuprofen administered twice daily for 2 weeks. The results showed a significantly greater decrease in pain after 2 weeks with the patients receiving PEA compared to Ibuprofen.
ADJUNCTIVE THERAPY IN DEPRESSIVE DISORDERS
PEA affects endocannabinoid signalling through Peroxisome Proliferator-Activated Receptor Alpha (PPAR-A) activation and affects indirect regulation of microglial cannabinoid type 2 receptor expression, with several studies illustrating the beneficial effects of PEA as a neuronal anti-inflammatory.
In a double-blinded RTC conducted by Ghazizadeh-Hashemi et al., 600mg of PEA administered twice daily in addition to Citalopram for 6 weeks was shown to significantly improve depressive symptoms with rapid onset of antidepressant effects compared to the placebo group who only received Citalopram alone.
